Zhang Yiqun, Wei Hui, Tang Kejing, Lin Dong, Zhang Cuiping, Mi Yingchang, Wang Lin, Wang Cuicui, Wang Min, Wang Jianxiang
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P.R. China.
Genet Test Mol Biomarkers. 2012 Aug;16(8):991-5. doi: 10.1089/gtmb.2011.0323. Epub 2012 Jul 18.
Mutations at arginine 132 of isocitrate dehydrogenase 1/2 (IDH1/2) have recently been demonstrated to be recurrent gene alterations in acute myeloid leukemia (AML). Subsequently, this mutation was also found in a variety of other hematologic malignancies, including myelodysplastic syndromes, myeloproliferative diseases, and non-Hodgkin lymphoma. Only a few cases were so far identified in acute lymphoblastic leukemia (ALL). To study the IDH status in ALL patients, we analyzed 54 adult and 34 pediatric ALL samples' IDH1/2 gene.
Three adult cases and no pediatric case with an isocitrate dehydrogenase 1 (IDH1) mutation were identified. No isocitrate dehydrogenase 2 (IDH2) mutation was identified in the total of 88 samples. The frequency of the IDH1 mutation in adult ALL was 5.5%. Among the three IDH1-mutated patients, two had normal karyotype and expressed the myeloid lineage markers. All three patients with an IDH1 mutation relapsed or died within 6 months.
The results suggested that the IDH1 R132 mutation might be a recurrent gene alteration in ALL; patients carrying the mutation have a trend to aberrantly express myeloid antigen and the mutation may imply a dismal outcome.
异柠檬酸脱氢酶1/2(IDH1/2)第132位精氨酸突变最近被证实是急性髓系白血病(AML)中常见的基因改变。随后,这种突变也在多种其他血液系统恶性肿瘤中被发现,包括骨髓增生异常综合征、骨髓增殖性疾病和非霍奇金淋巴瘤。到目前为止,仅在急性淋巴细胞白血病(ALL)中发现了少数病例。为了研究ALL患者的IDH状态,我们分析了54例成人和34例儿童ALL样本的IDH1/2基因。
鉴定出3例成人病例存在异柠檬酸脱氢酶1(IDH1)突变,儿童病例未发现IDH1突变。在总共88个样本中未发现异柠檬酸脱氢酶2(IDH2)突变。成人ALL中IDH1突变的频率为5.5%。在3例IDH1突变患者中,2例核型正常并表达髓系谱系标志物。所有3例IDH1突变患者均在6个月内复发或死亡。
结果表明,IDH1 R132突变可能是ALL中常见的基因改变;携带该突变的患者有异常表达髓系抗原的趋势,且该突变可能预示着不良预后。